Skip to main content
Passa alla visualizzazione normale.

ROBERTA BIVACQUA

GPCR Inhibition in Treating Lymphoma

  • Authors: Barreca M.; Spano' V.; Raimondi M.V.; Bivacqua R.; Giuffrida S.; Montalbano A.; Cavalli A.; Bertoni F.; Barraja P.
  • Publication year: 2022
  • Type: Review essay (rassegna critica)
  • OA Link: http://hdl.handle.net/10447/537453

Abstract

G protein-coupled receptors (GPCRs) are important classes of cell surface receptors involved in multiple physiological functions. Aberrant expression, upregulation, and mutation of GPCR signaling pathways are frequent in many types of cancers, promoting hyperproliferation, angiogenesis, and metastasis. Recent studies showed that alterations of GPCRs are involved in different lymphoma types. Herein, we review the synthetic strategies to obtain GPCR inhibitors, focusing on CXCR4 inhibitors which represent most of the GPCR inhibitors available in the market or under preclinical investigations for these diseases.